Extended Data Table 2 Resistance profile at baseline: non- nucleoside reverse transcriptase inhibitors

From: Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial

  1. Data are n (%). Percentage is the proportion of sequences that have the specified mutation. NNRTI resistance mutations are those listed in the 2022 edition of the IAS–USA drug resistance mutations list (L100I, K101EP, E138AGKQR, V179L, Y181CIV,
  2. Y188L, H221Y, F227C, M230IL for rilpivirine). NNRTI drug- resistance mutations were disregarded if they were APOBEC- context drug resistance mutations occurring on a sequence considered to be affected by APOBEC editing, indicated by the presence of at least one signature APOBEC mutation (as listed in the Stanford database). There were 33 sequences in the long-acting therapy group and 30 sequences in the oral therapy group that were considered to be affected by APOBEC editing. The rilpivirine resistance mutations disregarded for this reason are M230I in 12 participants and E138K in 2 participants (one with M230I) in the long-acting therapy group; and M230I in 12 participants in the oral therapy group. Additional NNRTI resistance mutations disregarded for this reason are G190E in 2 participants in the long-acting therapy group. Table adapted with permission from ref. 8, Elsevier.
Back to article page